Perinatal HIV Care and Prevention: A Case-Based Discussion

Susan Cu-Uvin, MD
Professor Obstetrics, Gynecology, and Medicine
The Warren Alpert Medical School
Brown University
Providence, Rhode Island

Learning Objectives
After attending this presentation, learners will be able to:

- Select the recommended antiretroviral therapy for women planning to get pregnant and during pregnancy
- Initiate treatment for acute HIV infection during pregnancy
- Initiate preexposure prophylaxis to prevent HIV transmission during pregnancy
- Describe HIV infection- and breastfeeding-related issues

Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years
Dr Cu-Uvin receives royalties from UpToDate. (Updated 9/20/21)
Case 1:

- A 28 y.o. (G1P0) with newly diagnosed HIV infection discovered during prenatal visit
- 10 weeks age of gestation by ultrasound dating
- Asymptomatic
- Initial: CD4 count of 300 cells/ul and HIV-RNA 300,000c/mL
- Other labs are normal, no other medical co-morbidities, awaiting HLA-B5701 result

What regimen would you choose?

1. DTG/ABC/FTC
2. DTC/ TDF/FTC
3. EFV/TDF/3TC
4. RPV/TDF/FTC
5. BIC/TAF/FTC

Which antiretrovirals are not currently recommended for pregnancy

1. BIC/ TDF/FTC
2. DTG/ABC/FTC
3. DRV/cobicistat
4. ATV/cobicistat
5. #1,3 and 4
**Preferred Initial Regimens in Pregnancy**

<table>
<thead>
<tr>
<th>NRTI Backbone</th>
<th>INSTI</th>
<th>Protease Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC/3TC</td>
<td>DTG/ABC/3TC (FDC)</td>
<td>ATV/r</td>
</tr>
<tr>
<td>TDF/FTC or TDF/3TC</td>
<td>DTG plus a Preferred Dual NRTI Backbone</td>
<td>DRV/r</td>
</tr>
<tr>
<td>TDF/FTC or TDF/3TC</td>
<td>ABC plus a Preferred Dual NRTI Backbone</td>
<td>RAL plus a Preferred Dual NRTI Backbone</td>
</tr>
</tbody>
</table>

- **ABC/3TC** not to be used in persons positive for HLA B-5701.
- DTG requires HLA B-5701 testing.
- RAL has to be given twice daily.
- Potential renal toxicity of TDF.

**Case 2**

- 35 y.o. PLHIV, G3P2, had a negative HIV test at her first trimester visit. She went to visit her spouse and family in Zambia during her pregnancy. Her obstetrician considered her high risk of acquiring HIV and did a third trimester HIV testing at 34 weeks AOG when she resumed prenatal care. She has seroconverted and is now HIV positive.
- Her CD4 count is 100 cells/ul and PVL is 400,000 c/mL
- She is asymptomatic and all other labs are normal.
- HLA B-5701 testing results take 2 weeks.
- HIV genotyping was sent.

**What is the best medical decision for this patient?**

1. Wait for HIV genotypic testing before starting antiretroviral therapy.
2. Wait for HLA-B5701 results because ABC is recommended treatment for pregnant patients.
3. 3. Start antiretroviral treatment immediately to attain rapid viral suppression with DTG/TDF/FTC and start PCP prophylaxis.
4. Start antiretroviral therapy but she does not need PCP prophylaxis.
Case 3

• H.W. is 21 y.o. was perinatally infected with HIV. She comes to clinic due to amenorrhea of 10 weeks. Her pregnancy test is positive. She has been exposed to several antiretrovirals since birth. HIV resistance testing shows the following mutations: K65R, M184V, K103. Her CD4 count is 386 cell/ul and her PVL is <20 on DTG with DRV/r.

What would you do?

• 1. Send for integrase resistance testing and entry inhibitors resistance testing
• 2. Absolutely change her current regimen because she has no recommended NRTI backbone in her current regimen
• 3. She should continue her antiretroviral therapy during pregnancy because the regimen is effective in suppressing viral replication
• 4. Consider adding maraviroc to her current regimen

Case 4

• T.W. is 31 y.o. G2P2, who has been HIV-infected for 6 years by a previous partner. She is currently on DTG/ABC/3TC with a CD4 count of 500 and PVL <20 c/mL. She has been adherent to her medications and her PVL has been undetectable for 5 years. She has met a new partner who is HIV negative. They are desirous to have a pregnancy. However, her partner is very worried about acquiring HIV and has asked for advice regarding PrEP. They both tested negative for any sexually transmitted diseases.
Which statement is correct?

- 1. When partners have different HIV status, sexual intercourse without a condom allows for conception with effectively no risk of sexual transmission to the partner without HIV if the partner with HIV is on ART and has achieved sustained viral suppression (U=U: undetectable = untransmissible).
- 2. Her HIV negative partner absolutely needs to start PrEP before any attempts at conception.
- 3. HIV perinatal transmission remains high despite ART and they should consider adoption as their best option.
- 4. There will never be a need for her partner to start PrEP even if she becomes non-adherent to her ART since she has had undetectable PVL for 5 years.

Case 5

I.M. is a Liberian woman who just gave birth to a healthy baby girl whose initial HIV testing is negative. I.M. is on DTG/ABC/FTC and her CD4 is 500 with an undetectable PVL at <20 c/mL over the past 3 years. She is very adherent to her therapy. She has disclosed her HIV status to her family but no one in her community knows about her HIV infection. She is firm in her decision to breastfeed her baby despite knowing the current recommendation in the US not to breastfeed when someone has HIV infection.

How can you best help I.M.?

- 1. Refuse to continue being her doctor because she is going against your advice for her not to breastfeed.
- 2. If she is to breastfeed, advice her that her baby should continue antiretroviral prophylaxis for the full duration of breastfeeding even if she has sustained viral suppression on her ART.
- 3. She should breastfeed exclusively for up to 6 months postpartum, followed by breastfeeding in combination with introduction of complementary foods.
- 4. Develop a plan for weaning and rapid weaning over a few days is recommended.